https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-20 / Cancer Immunol. Immunother. 2012 Oct;61(10):1791-804
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-20 / Cancer Immunol. Immunother. 2012 Oct;61(10):1791-8042012-03-20 00:00:002019-02-15 08:48:48Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-15 / J. Biomed. Biotechnol. 2012;2012:425476
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-15 / J. Biomed. Biotechnol. 2012;2012:4254762012-03-15 00:00:002019-02-15 08:39:57Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-15 / Clin. Dev. Immunol. 2012;2012:397648
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-15 / Clin. Dev. Immunol. 2012;2012:3976482012-03-15 00:00:002019-02-15 08:50:43Immunotherapy using dendritic cells against multiple myeloma: how to improve?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-08 / Arch. Virol. 2012 Jun;157(6):1011-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-08 / Arch. Virol. 2012 Jun;157(6):1011-82012-03-08 00:00:002012-03-08 00:00:00Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-07 / Breast Cancer Res. 2012 Mar;14(2):R39
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-07 / Breast Cancer Res. 2012 Mar;14(2):R392012-03-07 00:00:002019-02-15 08:50:03Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-01 / Expert Rev Vaccines 2012 Mar;11(3):287-302
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-01 / Expert Rev Vaccines 2012 Mar;11(3):287-3022012-03-01 00:00:002019-02-15 08:52:44Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-01 / Future Microbiol 2012 Mar;7(3):347-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-01 / Future Microbiol 2012 Mar;7(3):347-672012-03-01 00:00:002019-02-15 09:21:32Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-01 / Pancreas 2012 Mar;41(2):195-205
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-01 / Pancreas 2012 Mar;41(2):195-2052012-03-01 00:00:002019-02-15 08:52:32Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-01 / J Hepatobiliary Pancreat Sci 2012 Mar;19(2):171-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-01 / J Hepatobiliary Pancreat Sci 2012 Mar;19(2):171-82012-03-01 00:00:002012-03-01 00:00:00Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-02-29 / Neuroendocrinology 2013;97(1):26-34
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-02-29 / Neuroendocrinology 2013;97(1):26-342012-02-29 00:00:002019-02-15 09:22:48Virotherapy of neuroendocrine tumors
